Gyroscope - About the company
Gyroscope is an acquired company based in Stevenage (United Kingdom), founded in 2016. It operates as a Developer of gene therapies for eye diseases. Gyroscope has raised $255M in funding from investors like Syncona, Forbion and Sanofi, with last known valuation of $*****. The company has 3154 active competitors, including 1074 funded and 786 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.
Company Details
Developer of gene therapies for the treatment of eye diseases. The company focuses on a retinal disease, age-related macular degeneration (AMD). The Company’s lead product, GT005, is a novel retinal gene therapy aiming at delivering a targeted, one-off treatment for the progressive visual impairment caused by dry AMD in patients by locally modulating complement activity.
- Website
- gyroscopetx.com
- Social
- Email ID
- *****@gyroscopetx.com
- Phone Number
- +44 **********
Key Metrics
Founded Year
2016
Location
Stevenage, United Kingdom
Stage
Acquired
Total Funding
$255M in 5 rounds
Latest Funding Round
Last Known Valuation
$***** as on Dec 22, 2021
Ranked
688th among 3154 active competitors
Annual Revenue
£0 - £1M as on Dec 31, 2024
Employee Count
50 - 199 as on Mar 01, 2026
Investment & Acquisitions
Exit Details
Acquired by Novartis (Dec 22, 2021)
Legal entities associated with Gyroscope
Gyroscope is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
GYROSCOPE THERAPEUTICS HOLDINGS PLC CIN: 13086765 , United Kingdom, Active | Dec 16, 2020 | - | - | |
Gyroscope Therapeutics Limited CIN: 10131257 , United Kingdom, Active | Apr 17, 2016 | £0 - £1M (As on Dec 31, 2024) | 100 (As on Dec 31, 2023) |
Gyroscope's acquisition details
Click here to take a look at Gyroscope's acquisition in detail
Sign up to download Gyroscope's company profile
Gyroscope's funding and investors
Gyroscope has raised a total funding of $255M over 5 rounds. Its first funding round was on 2016. Its latest funding round was a Series C round on Nov 08, 2021 for $*****. 1 investor participated in its latest round. Gyroscope has 18 institutional investors and 35 angel investors.
Here is the list of recent funding rounds of Gyroscope:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 08, 2021 | 3348020 | Series C | 8782066 | 3921705 | 9058917 | 5962569 |
Mar 26, 2021 | 8617546 | Series C | 7331758 | 2371279 | 4655414 | |
Sep 03, 2019 | 7087313 | Series B | 2445732 | 9507412 |
Access funding benchmarks and valuations. Sign up today!View details of Gyroscope's funding rounds and investors
Gyroscope's founders and board of directors
Founder? Claim ProfileGyroscope's employee count trend
Gyroscope has 50 - 199 employees as of Mar 26. Here is Gyroscope's employee count trend over the years:
Uncover Gyroscope's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Gyroscope's Competitors and alternates
Top competitors of Gyroscope include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Gyroscope, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
688th | Gyroscope 2016, Stevenage (United Kingdom), Acquired | Developer of gene therapies for eye diseases | $255M | 40/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Gyroscope's competitors? Click here to see the top ones
Gyroscope's Investments and acquisitions
Gyroscope has acquired Orbit Biomedical. Gyroscope has not made any investments as of now.Reports related to Gyroscope
Here is the latest report on Gyroscope's sector:
News related to Gyroscope
Filter this list•
AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs OfficerBusiness Wire•Sep 28, 2023•AnHeart Therapeutics, Gyroscope
•
Syncona suffers negative valuation hit as Novartis discontinues GT005Shareprices•Sep 11, 2023•Syncona, Novartis, Gyroscope
•
AnHeart Therapeutics Appoints Edward Lang Jr. as Chief Business OfficerBusiness Wire•Apr 03, 2023•AnHeart Therapeutics, Gyroscope, Novartis, Bristol-Myers Squibb and 1 other
•
Gyroscope Raises $4.5M in Seed FundingFinSMEs•Mar 09, 2023•Gyroscope, Placeholder, Galaxy Venture Capital, Maven 11 and 6 others
•
Sonoma Biotherapeutics Appoints Jessica Stitt as Chief Financial OfficerBusiness Wire•Sep 07, 2022•Sonoma Biotherapeutics, Gyroscope
•
Portfolio company Gyroscope Therapeutics to be acquired for up to $1.5 billionCambridge Innovation Capital•May 12, 2022•Cambridge Innovation Capital, Gyroscope, Novartis
•
Syncona completes USD1.5 billion sale of Gyroscope to NovartisMorningstar•Feb 18, 2022•Syncona, Gyroscope, Novartis
•
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindnessGlobeNewswire•Dec 22, 2021•Novartis, Gyroscope, Sanofi, Novartis and 1 other
•
Gyroscope Therapeutics Announces Appointment of Tony Adamis to Board of DirectorsBusiness Wire•Dec 07, 2021•Gyroscope, Genentech
•
Sanofi invests up to $60m in Gyroscope TherapeuticsBioPharma-Reporter•Nov 09, 2021•Sanofi, Gyroscope, Mintos, Syncona
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Gyroscope
Explore our recently published companies
- Island Outdoor - Jamaica based, 2011 founded, Unfunded company
- Lab Cog - South Korea based, Unfunded company
- Dakshitha Wickremasinghe - Unfunded company
- Awet - Greenwich based, 2020 founded, Unfunded company
- GOODMIND - Turin based, Unfunded company
- Digital360 Technologies - Singapore based, 2021 founded, Unfunded company
